Summary
Ten patients with acromegaly were treated with the long-acting somatostatin analogue, Sandostatin (SMS 201-995, octreotide) for more than one year. Computerized tomography was performed before and on 4 different occasions during the treatment. Sella turcica volumes were calculated in nine patients and showed a gradual decrease in all, averaging 32%±14.6%,P<0.001 at the end of the study, which is probably indicative of a simultaneous reduction in adenoma size.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Williams RA, Jacobs HS, Kurtz AM, Millar JGD, Oakley NW, Spathis GS, Sulway MJ, Nabarro JDN (1975) The treatment of acromegaly with special reference to transsphenoidal hypophysectomy. Quart J Med 44: 79–98
Quabbe H-J (1982) Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation and bromocriptine: results in 230 patients. Clin Endocrinol (Oxf) 16: 107–119
Zervas NT (1987) Multicenter surgical results in acromegaly. In: Lüdecke DK, Tolis G (eds) Growth hormone, growth factors, and acromegaly (Progress in Endocrine Research and Therapy, vol 3). Raven Press, New York, pp 253–257
Eastman RC, Gorden P, Roth J (1979) Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 48: 931–940
Wass JAM, Moult PJA, Thorner MO, Dacie JE, Charlesworth M, Jones AE, Besser GM (1979) Reduction in pituitary tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet II: 66
Sachdev Y, Tunbridge WMG, Weightman DR, et al. (1975) Bromocriptine therapy in acromegaly. Lancet II: 1164–1168
Belforte L, Cammanni F, Chiodini PG, et al. (1977) Long-term treatment with 2-Br-alpha ergocryptine in acromegaly. Acta Endocrinol (Copenh) 85: 235–248
Clayton RN, Vrionides Y, Lynch SS, et al. (1978) Response of acromegaly to long-term bromocriptine therapy: a biochemical and clinical assessment. Acta Endocrinol (Copenh) 89: 469–482
Lamberts SWJ (1988) Sandostatin in the Treatment of Acromegaly. Springer, Berlin Heidelberg New York
Christensen SE, Weeke J, Ørskov H, Møller N, Flyvbjerg A, Harris AG, Lund E, Jørgensen J (1987) Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegaly patients. Clin Endocrinol 27: 297–306
Cobb WE, Jackson IMD (1989) Short-term recovery of visual field loss in acromegaly during treatment with a long-acting somatostatin analogue. Am J Med 86: 496–497
Barakat S, Melmed S (1989) Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostain analogue, Octreotide. Arch Intern Med 149: 1443–1445
Barnard LB, Granthan WG, Lamberton P, O'Dorisio TM, Jackson IMD (1986) Treatment of resistant acromegaly with a longacting somatostatin analogue (SMS 201-995). Ann Intern Med 105: 856–862
Ørskov H, Weeke J, Christensen SE, Nielsen S, Flyvbjerg A, Jørgensen JOL, Møller N, Harris AG (1988) Observations during a clinical trial of Sandostatin in acromegalic patients. In: Lamberts SWJ (ed) Sandostatin in the treatment of acromegaly. Springer, Berlin Heidelberg New York, pp 82–88
Ørskov H, Thomsen AG, Yde H (1968) Wick-chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature 219: 193–195
DiChiro G, Nelson KB (1962) The volume of the sella turcia. AJR 87: 989–1008
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lund, E., Jørgensen, J., Christensen, S.E. et al. Reduction in sella turcica volume. Neuroradiology 33, 162–164 (1991). https://doi.org/10.1007/BF00588258
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00588258